This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Access ground breaking bioprocessing, manufacturing & supply chain strategies to revolutionize your cell, gene and CAR-T clinical and late stage programs.

Learn how industry leaders are driving the successful commercialization of these life changing products

Access Key Industry Updates & Scientific Insights Across the Cell & Gene Therapy Spectrum


Monitoring Quality Across the Process - Process and Automated Analytics for Cell and Gene Therapies
Monitoring Quality Across the Process - Process and Automated Analytics for Cell and Gene Therapies
  • Developing potency strategies for gene therapy products
  • Augmenting Automated Analytics for Cell & Gene Therapy Manufacture
  • Analytical tools for a fast and robust commercial vector process
  • Evolution in gene transfer technology and its potential role in saving money longer term
Technologies and Novel Platforms for Efficient Upstream and Downstream Processes
Technologies and Novel Platforms for Efficient Upstream and Downstream Processes
  • Closed, automated and controlled upstream processing for iPSC-derived cell therapies
  • Upstream Raw Material Variation Monitoring and Control Strategies
Strategies for Optimized Process Development
Strategies for Optimized Process Development
  • Manufacturing Process & Product Development Efforts
  • Process Validation and CPV for Cell and Gene Therapy
  • Creation of Fit-for Purpose Devices and an All-in-One Automated Platform 

Translation from Small to Commercial Scale Manufacturing
Translation from Small to Commercial Scale Manufacturing
  • Large scale gene modification
  • Strategizing an economically viable manufacturing journey
  • Instrumentation and mechanisms to drive efficient therapies
Critical Challenges in Effective Scalability
Critical Challenges in Effective Scalability
  • Reinvention and Optimization of Vector Production
  • New manufacturing models for autologous cell therapies
Manufacturing Feasibility: Ensuring a Financially Viable Strategy
Manufacturing Feasibility: Ensuring a Financially Viable Strategy
  • Gene therapy productivity: Viral vector supply and demand
  • Feedback from the Industry Alliance Partnership (IAP) & CIRM Partnership and Commercialization Opportunities
  • PANEL: CMO landscapes for new product initiatives: Novel outsourcing models

Single-Use Technologies for Cell and Gene Therapies

This 1-day hands-on course (held on August 10, 2020) provides an Introduction to Single-Use Technologies and the specific attributes and quality needs when implementing Single-Use Technologies in Cell and Gene Therapy Manufacturing. Course participants will experience the latest Single-Use products first hand during the lab portion of the course.  

Course Instructor: James Dean Vogel, P.E., Founder of The BioProcess Institute

Connect with Global Scientists and Decision Makers Working Across Cell & Gene Therapy

Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.  

(Companies A-L) Contact Jennifer Wickett: JWickett@knect365lifesciences.com | +1-857-504-6694 

(Companies M-Z) Contact Blake Shuka: BShuka@knect365lifesciences.com | +1-857-504-6684